Medicenna Therapeutics (TSE:MDNA) Sets New 1-Year Low – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price reached a new 52-week low on Thursday . The company traded as low as C$0.34 and last traded at C$0.34, with a volume of 9582 shares. The stock had previously closed at C$0.35.

Medicenna Therapeutics Trading Down 1.4%

The company has a debt-to-equity ratio of 4.79, a quick ratio of 4.65 and a current ratio of 1.52. The company has a market capitalization of C$31.84 million, a P/E ratio of -1.57 and a beta of 2.96. The company’s fifty day simple moving average is C$0.42 and its 200-day simple moving average is C$0.65.

Medicenna Therapeutics (TSE:MDNA) last posted its quarterly earnings results on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. Research analysts predict that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.